Shirai, Kohji; Tanaka, Michitaka; Fujita, Toru; Fujii, Yuka; Shimomasuda, Masatsugu; Sakai, Soichi; Samukawa, Yoshishige published the artcile< Safety of Excessive Visceral Fat Reduction with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese Individuals: A Long Term Clinical Study>, Recommanded Product: (S)-(S)-1-((2S,3S)-3-Hexyl-4-oxooxetan-2-yl)tridecan-2-yl 2-formamido-4-methylpentanoate, the main research area is orlistat lipase inhibitor visceral fat antiobesity agent; Body weight; Efficacy; Japanese; Lipase inhibitor; Long-term administration; Obesity; Orlistat; Safety; Visceral fat; Waist circumference.
Introduction: Orlistat is an inhibitor of pancreatic lipase and is used as an anti-obesity drug in many countries. However, there are no data available regarding the effects of orlistat on visceral fat (VF) accumulation in Japanese individuals. Therefore, this study aimed to analyze the efficacy and safety of 52 wk of orlistat administration in Japanese individuals. Methods: Orlistat 60 mg was administered orally three times daily for 52 wk to Japanese participants with excessive VF accumulation and without dyslipidemia, diabetes mellitus, and hypertension (metabolic diseases). Participants were also counseled to improve their diet and to maintain exercise habits. We defined excessive VF accumulation as a waist circumference (WC) of ≥ 85 cm for males and ≥ 90 cm for females, which corresponds to a VF area of 100 cm2. Adverse reactions, clin. laboratory tests, VF, WC, body weight (BW), etc., were monitored throughout the study period. Results: VF, WC, and BW were significantly reduced at week 52 from baseline; the mean ± standard error rate of change was – 21.52% ± 1.89%, – 4.89% ± 0.45%, and – 5.36% ± 0.56%, resp., and continued to reduce throughout the 52 wk; these significantly reduced at whole term compared with baseline. Most adverse reactions were defecation-related symptoms such as oily spotting and flatus with discharge (flatus with small amounts of stool or oil) due to the pharmacol. effects of the lipase inhibitor. These symptoms were mostly mild, reversible, and recognizable by the participants; none were serious or severe. No participants discontinued by medical judgment about adverse reactions, and the drug could be administered continuously. Conclusion: VF, WC, and BW were reduced from week 4 to week 52, indicating the effect of long-term orlistat administration. Moreover, it was well tolerated with an acceptable safety profile. Long-term administration of orlistat may be efficacious in reducing VF accumulation with safety when used in combination with diet and exercise. Trial Registration: This study is registered with the Japan Pharmaceutical Information Center (identifier: JapicCTI-184004). Funding: Funding for this study was provided by Taisho Pharmaceutical Co., Ltd.
Advances in Therapy published new progress about Antiobesity agents. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, Recommanded Product: (S)-(S)-1-((2S,3S)-3-Hexyl-4-oxooxetan-2-yl)tridecan-2-yl 2-formamido-4-methylpentanoate.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics